They talk about us
Watch the videos and read their transcriptsVideos
Kohen Avocats, for pharmacies, pharmacy groups and pharmaceutical companies
Pharmaceutical lawyer in France for pharmacies and drug companies
Buying a pharmacy, a transfer, an ARS or ANSM inspection, a CPAM overpayment claim, a complaint before the Order of Pharmacists or a distribution contract: as pharmaceutical lawyers in France, the firm examines your professional situation. Pharmacy owners, pharmacy groups and pharmaceutical companies receive support tailored to the planned project, the documents available and the procedure received.
The firm can be reached 24/7. Send the notification you received with its appendices so that we can identify the procedure concerned and check the deadlines specific to your case.
4,9/5
Average Google review rating270 reviews
I received very high-quality support from this criminal lawyer. His professionalism, his complete command of the case and his constant involvement at every stage of the proceedings deserve to be highlighted. Communication was clear, structured and responsive, with precise advice suited to my situation. I recommend this lawyer to anyone looking for a rigorous and effective criminal defence.
Mr Kohen handled my criminal case. I am very satisfied with the work he did and I recommend him to you without any hesitation.
Excellent criminal defence lawyer, he got me out of trouble in a protection order application made abusively by my ex
Very satisfied with the solution provided for my defence before the court. All the best
Hassan Kohen is a young, seasoned and highly competent lawyer. He is an excellent listener, shows great empathy and has a strong human sensitivity. Available and responsive, he has complete mastery of his profession.
I had a very good experience with Hassan Kohen. He took the time to listen to me carefully and to fully understand my situation. He is a lawyer who gives sound advice, kind and available, and who knows how to steer his clients in the right direction. I recommend him without hesitation to anyone looking for an attentive and competent professional.
Mr Kohen advised and supported us well. I thank him for everything he has done.
Pharmaceutical law
Urgent matters 24/7
Preliminary case review
Send your documents. Receive an analysis.
Hassan Kohen, pharmaceutical law lawyer
Lawyer at the Paris Bar, advising and defending pharmacy owners, pharmacy groups and pharmaceutical companies in their projects and proceedings.
Official profile in the directory of French lawyers (CNB) · 4.9/5 on Google (270 reviews)
Pharmacies, pharmacy groups and pharmaceutical companies
Pharmacy owners and pharmaceutical companies
Choose your situation
Your pharmaceutical business
You are a pharmacy owner, the head of a pharmacy group or the manager of a pharmaceutical company, and you must take a decision that commits your business. Pharmaceutical law governs the operation of the pharmacy (officine), the circulation of medicines and relations with the supervisory authorities. The firm examines your acquisition, your sale, your corporate structure or your transfer project on the basis of the documents available. It also prepares the observations required in response to an ARS inspection, a CPAM overpayment claim, a complaint before the Order of Pharmacists or an ANSM procedure. For pharmaceutical companies, the analysis covers in particular authorisations, the risk of stock shortages, advertising and distribution contracts. Each engagement distinguishes regulatory obligations, contractual commitments and the defence to be organised when your liability is called into question. This professional page complements our presentation of health law in France and, depending on your needs, refers to company law, public law and commercial disputes. Present your project or send the decision you received so that we can define the useful documents and the scope of our assistance.
A pharmacy to take over, an inspection to prepare for or a pharmaceutical company’s activity to frame?
Understanding your situation
Pharmacy owners, pharmaceutical companies and marketing authorisation holders: your needs
Your business and the authority concerned determine the first checks. Here you will find pharmacy projects, inspections, the obligations of pharmaceutical companies and the documents useful to your defence.
Pharmacy
Buying, selling or structuring a community pharmacy in France
The planned transaction must remain consistent with the operating conditions and with the structure that will carry your business.
Taking over a pharmacy calls for a joint reading of the licence, the articles of association, the contracts and the operating documents. Article L. 5125-11 of the French Public Health Code (Code de la santé publique) governs the ownership of the pharmacy and the companies that operate it. Article L. 5125-9 of the Public Health Code concerns the declaration of operation and changes affecting ownership.
Acquiring or selling
We examine the scope transferred, the contracts taken over, the seller’s commitments and the reservations revealed by the documents. This review makes it possible to prepare the questions to be resolved before signing and to define the warranties to be negotiated.
Organising an SEL or an SPFPL
Article R. 5125-18-1 of the Public Health Code imposes specific rules on pharmacy owners. The distribution of capital and voting rights is checked at each level of ownership, including indirect holdings.
Transferring or merging a pharmacy: preparing the project
The project requires checking the licence provided for by Article L. 5125-18 of the Public Health Code and the population service conditions of Article L. 5125-3 of the Public Health Code. We compare population data, access, the proposed premises and the situation of the pharmacies concerned.
A merger (regroupement) is also governed by Article L. 5125-5 of the Public Health Code, while certain configurations require examining the derogation in Article L. 5125-3-3 of the Public Health Code. The applicable territorial rules must be checked for the precise location of the project.
A transaction involving shares and a transaction involving the business itself call for different checks. The conditions of practice remain to be examined in both situations.
Pharmacy inspections
ARS inspection, CPAM overpayment claim or proceedings before the Order of Pharmacists
Identifying the procedure makes it possible to answer the complaints without confusing the powers of the different authorities.
ARS inspection
Article L. 5127-1 of the Public Health Code specifies who carries out pharmaceutical inspections. The firm analyses the report, compares each finding with the documents kept and prepares your observations with the corresponding supporting documents.
CPAM overpayment claim
Article L. 133-4 of the French Social Security Code (Code de la sécurité sociale) governs the recovery of overpayments (indus). The review covers in particular prescriptions, dispensing, invoices and the transactions identified by the fund.
Disciplinary proceedings before the Order
Article L. 4234-1 of the Public Health Code determines disciplinary jurisdiction according to the activity in question. Article L. 4234-6 of the Public Health Code governs penalties; the response must discuss the facts and the elements relevant to their assessment.
Separate financial penalty
Article L. 114-17-2 of the Social Security Code organises the health insurance penalty procedure. A repayment claim is not the same as this procedure, even when the same transactions are examined.
An inspection report, a complaint and a sanction decision do not call for the same response. The closure of an online sales website must not be treated as the closure of the physical premises.
Pharmaceutical companies and pharmacy groups
Pharmaceutical companies: product regulation and ANSM inspections
Distinguishing authorisations, product obligations and the company’s commitments.
Article L. 5124-1 of the Public Health Code defines the activities of pharmaceutical establishments. Article L. 5124-2 of the Public Health Code sets out the organisation around the responsible pharmacist (pharmacien responsable) and the delegate pharmacist. We examine the authorisation documents, the inspection reports and the actual allocation of responsibilities in the light of your activity.
Article L. 5313-1 of the Public Health Code governs ANSM inspections. The observations prepared must link each complaint to the technical documents, the exchanges kept on file and the corrective measures actually implemented.
Marketing authorisation of the medicine
Article L. 5121-8 of the Public Health Code concerns the marketing authorisation (autorisation de mise sur le marché, AMM). A change of indication calls for a separate analysis of the data in the file and of reimbursement issues.
Product availability
Article L. 5121-32 of the Public Health Code requires the ANSM to be informed as soon as the risk of a stock shortage or the shortage itself becomes known. The chronology of alerts and declarations is a central document in the response.
Contracts, distribution, advertising and commercial relations
Distribution, supply and pharmacy group contracts must be compared with the authorised activities and the responsibilities actually assumed. Article L. 5122-1 of the Public Health Code distinguishes advertising for medicinal products from communications excluded from that classification. Article L. 5122-9 of the Public Health Code governs the advertising approval (visa de publicité) for advertising aimed at healthcare professionals.
Agreements with healthcare professionals also call for an analysis of the anti-gift rules (dispositif anti-avantages) and of transparency requirements, in particular under Article L. 1453-8 of the Public Health Code. Publishing a benefit is not enough to establish that it is lawful.
Professional defence
Your defence when your professional liability is called into question
Building a response based on the acts performed, the contemporaneous documents and the exact nature of the allegations.
Identifying what you are accused of
We distinguish a claim addressed to the pharmacy or the pharmaceutical company, disciplinary proceedings before the Order, an administrative inspection and any criminal consequences.
Keeping the relevant documents
Prescriptions, registers, electronic claims transmissions, successive package leaflets and correspondence make it possible to reconstruct the facts without altering the original documents.
Examining the basis of the claim
As regards the producer’s liability, Article 1245-8 of the French Civil Code (Code civil) concerns proof of the damage, the defect and the causal link. Each element must be analysed separately.
Preparing the observations and the defence
The firm organises the documents, identifies the points open to challenge and examines the necessary technical explanations with the people your case requires.
Article 1245-9 of the Civil Code rules out treating an administrative authorisation as automatic protection against the producer’s liability. Insurance cover and exchanges with the insurer are examined on the basis of the contractual documents available.
Your case
Our assistance: a dedicated lawyer, useful documents and fees
Defining the engagement on the basis of your project, your documents and the procedure actually under way.
Hassan Kohen, avocat at the Paris Bar, examines your request to specify the work proposed, the documents needed and the terms of his involvement. The scope of the engagement and the fees are discussed before the corresponding assistance begins.
For an acquisition or a sale: licence, articles of association, distribution of capital, draft deed, contracts and operating documents relevant to the takeover.
For a transfer or a merger: the application filed, ARS decisions, plans, territorial data and exchanges concerning the proposed premises.
For an inspection or a complaint: the full report, notification, appendices, correspondence and evidence of the corrective measures already taken.
For a pharmaceutical company: authorisations, product file, inspection reports, package leaflets, contracts and a documented chronology of the alerts received.
For a first written opinion, the preliminary case review at €80 incl. VAT can be requested using the form on this page.
You can present your situation on +33 6 89 11 34 45 and send the documents already available. Any further checks are specified once the file has been read.
Your questions
Questions from pharmacists and pharmaceutical companies
Answers to help you prepare your professional decisions and understand the distinctions that matter for your case.
What should I check before buying or selling a pharmacy in France?
Acquiring a pharmacy begins with identifying what is being transferred: the business (fonds), company shares or a more complex structure. Article L. 5125-11 of the French Public Health Code (Code de la santé publique) governs the ownership of the pharmacy and the companies that operate it. Article L. 5125-9 of the Public Health Code concerns declarations of operation and changes affecting ownership. These rules must be read together with the licence and your professional project.
The firm examines the documents provided by the seller, the draft deed, the contracts taken over and the commitments that would remain after signing. Inspection reports, exchanges with the authorities and billing difficulties may also change the analysis of the file. Missing information, identified irregularities and disagreements relating only to the commercial terms of the transaction must be distinguished.
This review makes it possible to prepare the requests for documents, the reservations to be lifted and the warranties to be discussed between the parties. For a takeover by a company, we also check the distribution of capital and voting rights. This analysis does not replace verification of the conditions specific to your professional practice.
How should the capital of a pharmacists’ SEL or SPFPL be organised?
A structure suited to another health profession cannot be transposed to a community pharmacy without checking it. Article R. 5125-18-1 of the Public Health Code imposes specific rules on the majority of the capital and voting rights. A majority SPFPL must itself meet the conditions relating to the owners of the pharmacy concerned. Article L. 5125-12 of the Public Health Code also provides for direct holding by each practising partner.
The review covers the entire chain of ownership, distinguishing practising partners, indirect holdings and the rights attached to the shares. Article R. 5125-19 of the Public Health Code prohibits direct or indirect holding by persons practising another self-employed health profession. The partners eligible for an SPFPL are governed in particular by Article R. 5125-24-2 of the Public Health Code.
To have your structure examined, send the articles of association, shareholders’ agreements, ownership charts and the detailed distribution of voting rights. The firm compares these documents with the partners’ actual professional situation and the planned transactions. The legal structure must be verified before the financing or the entry of an investor is treated as finally settled.
Can my pharmacy transfer project be authorised?
Whether a transfer is feasible depends on the planned location, the population service conditions and the features of the project submitted to the ARS. Article L. 5125-3 of the Public Health Code governs service to the population and the preservation of its supply of medicines. Article L. 5125-3-2 of the Public Health Code sets out the conditions relating to access, premises and the population served. A commercially attractive location is therefore not enough to show that the legal conditions are met.
The Bordeaux Administrative Court of Appeal states: “The resident population must be understood, in addition, where applicable, to the seasonal population, as only the population domiciled in those neighbourhoods or having a stable residence there.” (our translation) (CAA de BORDEAUX, 14 November 2024, No. 23BX03216). This decision encourages documenting the population concerned rather than counting only people who visit the area occasionally. It upholds the annulment of a transfer authorisation in the circumstances examined.
To prepare your application, we compare the plans, access, residential data and property projects with the applicable criteria. The file must also make it possible to understand the situation of the neighbourhood of origin and that of the receiving neighbourhood. The analysis covers your precise configuration, including where special provisions may change the conditions to be examined.
What documents should I prepare to merge several pharmacies?
A merger requires a file that makes it possible to understand the pharmacies concerned, the new location and the consequences of the project for service to the population. Article L. 5125-5 of the Public Health Code lays down conditions specific to mergers, in particular concerning the former premises and the merged licences. Article L. 5125-18 of the Public Health Code governs the licence issued by the ARS. The population service conditions must be examined together with any derogations applicable to the chosen configuration.
Gather the licences, the plans of the premises, the territorial data, the commitments relating to the new location and the correspondence already exchanged. The firm checks the consistency between the administrative project, the agreements concluded between owners and the legal structure that will operate the new pharmacy. The documents must make it possible to distinguish established elements from mere prospects that remain uncertain.
On the population served in a transfer dispute, the court held: “The resident population must be understood, in addition, where applicable, to the seasonal population, as only the population domiciled in those neighbourhoods or having a stable residence there.” (our translation) (CAA de BORDEAUX, 14 November 2024, No. 23BX03216). This reference point informs the preparation of territorial data without removing the need to check the rules specific to mergers. Finally, the analysis must coordinate the necessary authorisations with the contractual commitments made by each participant.
How should I respond to an ARS inspection report?
First, the findings of the report, the documents requested and any measures or procedures announced by the agency must be distinguished. Article L. 5127-1 of the Public Health Code governs pharmaceutical inspection and specifies the status of the officials concerned. Article L. 5472-1 of the Public Health Code provides for a system of financial penalties specific to breaches relating to pharmacies and retail distribution. An inspection alone does not allow you to infer the sanction that would be imposed.
The response must take up each finding and compare it with the documents available at the date of the facts. We distinguish contestable clerical errors, useful professional explanations and the corrective measures actually taken. Registers, internal procedures, storage records and staffing documents can inform this analysis.
Keep the full report, its appendices and the exchanges that took place before and after the visit. A general response about the usual quality of your practice does not replace the supporting documents expected for a specific complaint. The firm prepares observations consistent with the documents and examines separately any administrative, disciplinary or criminal follow-up.
How do I prepare my defence before the Order of Pharmacists?
The defence begins with reading the complaint, the documents disclosed and the notification specifying the procedure brought. Article L. 4234-1 of the Public Health Code determines disciplinary jurisdiction according to the activity in which the facts were committed. Article L. 4234-6 of the Public Health Code governs the possible sanctions. The analysis must cover whether the complaints are established, how they are characterised and the elements relevant to assessing the sanction.
In a case following an inspection, the Council of State (Conseil d’État) held that “these breaches, whatever the degree of seriousness of each of them, were such as to justify, taken together, a disciplinary sanction.” (our translation) (Conseil d'État, 21 July 2025, No. 496297). The complaints must therefore be examined individually, but also as a whole. This decision does not make it possible to predict the sanction applicable to another pharmacy.
We reconstruct the chronology, compare each complaint with contemporaneous documents and examine the corrections you can prove. Article R. 4235-1 of the Public Health Code must be read in its applicable version, given the changes to the code of ethics. The ways of challenging a decision of the Order differ from those relating to an administrative decision of the ARS.
Can I challenge a CPAM overpayment claim if the medicines were actually dispensed?
The fact that the medicines were actually dispensed is not always enough to defeat a repayment claim from the health insurance fund. Article L. 133-4 of the French Social Security Code (Code de la sécurité sociale) governs overpayments arising in particular from pricing, distribution and billing rules. A challenge requires checking the transactions identified, their justification and the precise grounds of the notification. An overall analysis of the amount claimed would not be enough to respond effectively.
The Court of Cassation held, in relation to irregular prescriptions, that “the fund was entitled to pursue recovery of the overpayment against the pharmacy that had filled those prescriptions” (our translation) (Cour de cassation, Deuxième chambre civile, 10 October 2019, No. 18-20.866). This judgment shows why prescriptions must be examined together with invoices and proof of dispensing. It does not mean that every claim by the fund is necessarily well founded.
The firm compares the disputed lines with the prescriptions, the electronic claims transmissions and any documented corrections. It checks for inconsistencies, duplicates and factual explanations that may change the calculation or the principle of the claim. The notification and its appendices must be sent in full in order to identify the observations to be made and the appropriate way to challenge it.
Can my pharmacy keep operating during a ban on practice?
A ban on practice (interdiction d’exercice) requires a precise examination of the decision, its scope and the conditions for any replacement that would allow the business to continue. Article L. 4234-6 of the Public Health Code governs disciplinary sanctions, while Article L. 4234-7 of the Public Health Code concerns appeals to the national chamber and their suspensive effect. These provisions do not allow it to be presumed that an owner may personally continue to practise despite a ban that has become enforceable.
In a case where the business continued without a proper replacement, the Council of State rejected the argument based on intention: “the alleged circumstance that the breaches committed by Mrs A... were not intentional has no bearing in this respect” (our translation) (Conseil d'État, 10 October 2023, No. 467215). Recruitment difficulties must therefore not be treated as implicit permission to continue practising.
The firm examines the decision received, the replacement documents and the actual allocation of tasks within the pharmacy. The commercial organisation of the establishment must be distinguished from the performance of the pharmaceutical acts covered by the ban. The texts applicable at the date of the facts and the replacement pharmacist’s situation require specific verification before any decision to keep the business running.
Does a criminal acquittal rule out any financial claim by the CPAM?
You need to read the operative part of the decision and identify what has been finally decided on each claim submitted. An acquittal (relaxe) must not be presented as automatically settling every financial issue raised by the health insurance fund. Article L. 133-4 of the Social Security Code governs the recovery of overpayments, which must be distinguished from the civil claims examined in criminal proceedings.
In the case decided by the Criminal Chamber, the Court reiterates that “the social security fund, which is not required to cover services that were irregularly billed, suffers a loss that must be compensated in full” (our translation) (Cour de cassation, Chambre criminelle, 17 February 2026, No. 25-81.335). The quashing concerns the fund’s civil claims, whereas the criminal acquittal is final. This judgment is therefore not a criminal conviction of the pharmacist.
To assess your situation, we examine the decisions handed down, the fund’s claims and the transactions to which they relate. The dates of prescriptions, dispensing and electronic claims transmissions must be compared with the documents relating to professional practice. This review makes it possible to distinguish the issues still in dispute from those already decided, without giving the judgment a wider scope than its operative part.
What precautions should I take to sell medicines online in France?
Article L. 5125-33 of the Public Health Code links the online sale of medicines to a pharmacy open to the public. Article L. 5125-34 of the Public Health Code limits it to medicines that are not subject to compulsory prescription. The prior declaration is governed by Article L. 5125-36 of the Public Health Code, with the arrangements set out in Article R. 5125-71 of the Public Health Code. The formalities and the practical operating conditions must be examined together.
In an older dispute concerning delivery, the Lyon Administrative Court of Appeal held: “a medicine ordered electronically and not collected in person at the pharmacy must be delivered directly to the patient’s home by the carrier, without being stored in any way whatsoever.” (our translation) (CAA de LYON, 9 July 2020, No. 18LY04341). This extract describes the arrangements examined under the texts applicable at the time. It does not validate the current regulatory delivery arrangements.
The decision concerned the closure of the website, not of the pharmacy’s physical premises. Article L. 5472-2 of the Public Health Code specifically addresses the regulation of the e-commerce website. For your business, the firm examines the declaration, the ordering channels, pharmaceutical supervision, storage and logistics contracts. The technical requirements specific to the website call for particular verification before a sales or delivery arrangement is adopted.
How should a pharmaceutical company prepare its observations after an ANSM inspection?
The response must start from the report received and identify the activities, products and breaches specifically examined by the agency. Article L. 5313-1 of the French Public Health Code (Code de la santé publique) governs ANSM inspections, in particular the review of activities and good practice. Article L. 5124-3 of the Public Health Code concerns the authorisation to open the establishment and substantial changes to it. The obligations examined therefore vary according to the activity and the decision under consideration.
The firm organises a documented response by comparing the inspection’s observations with internal procedures and the technical documents available. It distinguishes findings that can be factually challenged, acknowledged deviations and corrective measures whose implementation can be proved. The chronology of exchanges and the quality of the supporting documents must remain consistent across the company’s different departments.
Article L. 5471-1 of the Public Health Code provides for financial penalties whose regime depends on the breaches found. It does not set a single cap applicable to every situation. Send the report, the authorisations, the responses already sent and the documents relating to the corrections made. The analysis then makes it possible to prepare observations suited to the procedure actually brought.
How do I prepare an extension of indication for a medicine?
An extension of indication calls for an analysis of the file submitted, the available data and the conditions for varying the marketing authorisation (AMM). Article L. 5121-8 of the Public Health Code governs this authorisation, while Article L. 5121-9 of the Public Health Code provides in particular for its variations and for the decisions that may affect it. The authorisation question must remain separate from the reimbursement question.
The Council of State notes that “the file accompanying the application for an extension of therapeutic indication submitted by Zentiva France had to contain the relevant data making it possible to guarantee the safety and efficacy of the medicinal product” (our translation) (Conseil d'État, 13 June 2022, No. 456303). In that case, the challenge to the variation of the AMM was rejected. The annulment concerned only the disputed listing for reimbursement, on a separate ground.
For your project, we examine the planned application, the data relied on, the exchanges with the authority and any objections raised by a competitor. Questions of protection of a third party’s data call for an analysis specific to their use and to the file concerned. Preparation must make it possible to distinguish the conditions of the authorisation, the scientific evidence presented and the expected commercial consequences of the extension, without confusing these different levels.
Does the absence of an actual shortage rule out an ANSM sanction?
The risk of a shortage, the stock shortage itself and their actual consequences for supply must be distinguished. Article L. 5121-32 of the Public Health Code requires the ANSM to be informed as soon as the risk of a stock shortage or the shortage itself becomes known. Article L. 5121-31 of the Public Health Code concerns shortage management plans for the medicines concerned. Prevention and declaration are therefore obligations to be examined separately from the outcome achieved.
The Paris Administrative Court of Appeal held that “these circumstances have no bearing on the reality of the breach found, consisting of the late declaration of the risk of a stock shortage.” (our translation) (CAA de PARIS, 7 October 2026, No. 24PA05098). In that case, the absence of any supply disruption and the corrective measures did not cancel out the late declaration of the risk. The historical cap discussed in that decision must not be transposed as the current cap.
The firm reconstructs the chronology of alerts, information received, internal decisions and declarations sent to the agency. Evidence of prevention and corrective measures remains relevant to the analysis, without automatically neutralising an established delay. Each complaint must also be compared with the breach specifically targeted in the procedure before the company’s observations are prepared.
Can a communication aimed at healthcare professionals be regulated advertising?
A professional communication is not unregulated simply because it is addressed to pharmacists or prescribers. Article L. 5122-1 of the Public Health Code defines advertising for medicinal products and the communications excluded from it. Article L. 5122-2 of the Public Health Code requires in particular an objective presentation that is not misleading and is consistent with the marketing authorisation. The classification depends on the content, its purpose and the conditions of distribution.
Article L. 5122-9 of the Public Health Code governs the advertising approval (visa) for advertising aimed at healthcare professionals. For a communication aimed at the public, Article L. 5122-6 of the Public Health Code and Article L. 5122-8 of the Public Health Code call for a separate analysis. Institutional material, medical information and promotional presentation must therefore not be confused.
We examine the complete material, its recipients, the claims made and the documents to which they refer. For a pharmacy group or a pharmacy, communication about the business must also be distinguished from the promotion of a specific medicine. The firm identifies the points to be corrected and the checks needed before distribution, without assuming that a digital publication escapes the applicable rules.
Can a pharmaceutical company fund training or invite a healthcare professional?
Whether it can depends on the recipient, the nature of the benefit, its purpose and the regime applicable to the agreement. Article L. 1453-5 of the Public Health Code governs the prohibition on offering or promising the benefits concerned. Article L. 1453-7 of the Public Health Code provides for regulated exceptions, in particular for certain services, training or forms of hospitality. An alleged professional purpose is not enough to establish that all the conditions are met.
Article L. 1453-8 of the Public Health Code provides for a prior agreement accompanied by a declaration or an authorisation, depending on the applicable regime. The exclusions provided for by Article L. 1453-6 of the Public Health Code must also be examined without turning them into a general freedom. Article L. 1453-1 of the Public Health Code concerns transparency: publishing a benefit does not amount to authorising it.
The firm examines the draft agreement, the services expected, the recipients, the expenses covered and the supporting documents available. Regulatory thresholds are not assumed to be the same for all professions or all categories of benefits. They are checked as part of the analysis of the specific project, before the necessary formalities and the conditions for any implementation are determined.
How should a non-compete clause in a pharmacy group be analysed?
You need to identify the persons actually bound by the clause, the activities covered and the holdings its wording concerns. The agreement must be read in full, with its appendices, its definitions and the documents describing the companies concerned. An obligation entered into by a partner cannot be extended without examination to every person linked to that partner.
In the Pharmabest case, the Court of Cassation clarifies the scope of the clause: “but does not prohibit the manager of a partner of Pharmabest from managing or being a partner in a third-party company that does not carry on activities competing with those of Pharmabest” (our translation) (Cour de cassation, Chambre commerciale financière et économique, 13 November 2025, No. 24-20.373). The decision censures a distortion (dénaturation) of the clause. It concerns a network agreement and does not lay down the rules for selling a pharmacy.
This contractual question must also be distinguished from the professional rules on ownership, in particular those of Article R. 5125-18 of the Public Health Code. The firm examines the positions held, the direct and indirect holdings and the actual business of the companies concerned. This analysis makes it possible to discuss the scope of the clause and the claims made, without assuming that an outside holding necessarily amounts to a prohibited competing activity.
How do you defend a pharmaceutical company accused over a defective medicine?
The defence must distinguish the damage claimed, the alleged defect and the causal link, in accordance with Article 1245-8 of the French Civil Code (Code civil). Article 1245-3 of the Civil Code calls in particular for an examination of the product’s presentation and the safety that can legitimately be expected. Article 1245-9 of the Civil Code prevents an automatic absence of liability from being inferred solely from compliance with standards or the existence of an authorisation.
In the Depakine case, the Court of Cassation notes that “the presentation of Depakine, in the leaflet intended for patients, therefore did not contain the information that, among the possible side effects of the medicine, there was a teratogenic risk of particular seriousness” (our translation) (Cour de cassation, Première chambre civile, 27 November 2019, No. 18-16.537). It upholds the finding of a defect linked to information, while censuring the failure to respond to the argument relating to mandatory rules. The judgment does not establish any automatic exemption.
We examine the successive versions of the leaflet, the knowledge available when the product was put into circulation and the scientific evidence of causation. The grounds for exemption provided for by Article 1245-10 of the Civil Code must be proved under the conditions specific to the case. The defence is built on contemporaneous documents and identifiable objections, without confusing product authorisation, the information provided and the producer’s civil liability.
Which documents should I send for a first exchange with the firm?
State your professional status, the activity concerned and the decision you wish to prepare or challenge, then attach the documents already available. For a pharmacy, the licence, the articles of association, the contracts and the notifications received help to situate the file. For a pharmaceutical company, the authorisations, inspection reports and exchanges with the authority are often the first useful documents.
A pharmaceutical inspection under Article L. 5127-1 of the Public Health Code is not the same as an ANSM inspection under Article L. 5313-1 of the Public Health Code. An overpayment claim based on Article L. 133-4 of the Social Security Code calls for yet other checks. It is therefore better to send the full notification and its appendices rather than a summary of its main conclusions.
Add a chronology of the exchanges and state the steps already taken, the observations sent and the corrective measures actually implemented. The firm then identifies the additional documents needed, the questions to be resolved and the scope of the proposed engagement. Fees and the terms of assistance are discussed in light of this engagement, without assuming that an initial review covers every possible procedure.
References
Official texts and related pages
The sources for this page and the firm’s pages devoted to each situation.
Official texts and decisions
The articles below underpin the content of this page. The extracts from decisions and their official links appear in the corresponding answers.
- Article L. 5125-3 of the Public Health Code
- Article L. 5125-3-2 of the Public Health Code
- Article L. 5125-3-3 of the Public Health Code
- Article L. 5125-5 of the Public Health Code
- Article L. 4234-1 of the Public Health Code
- Article L. 4234-6 of the Public Health Code
- Article L. 4234-7 of the Public Health Code
- Article R. 4235-1 of the Public Health Code
- Article L. 133-4 of the Social Security Code
- Article L. 114-17-2 of the Social Security Code
- Article L. 5125-33 of the Public Health Code
- Article L. 5125-34 of the Public Health Code
- Article L. 5125-36 of the Public Health Code
- Article L. 5124-1 of the Public Health Code
- Article L. 5124-2 of the Public Health Code
- Article L. 5124-3 of the Public Health Code
- Article L. 5121-8 of the Public Health Code
- Article L. 5121-9 of the Public Health Code
- Article L. 5313-1 of the Public Health Code
- Article L. 5122-1 of the Public Health Code
- Article L. 5122-2 of the Public Health Code
- Article L. 5122-6 of the Public Health Code
- Article L. 5122-8 of the Public Health Code
- Article L. 5122-9 of the Public Health Code
- Article L. 1453-1 of the Public Health Code
- Article L. 1453-5 of the Public Health Code
- Article L. 1453-6 of the Public Health Code
- Article L. 1453-7 of the Public Health Code
- Article L. 1453-8 of the Public Health Code
- Article L. 5471-1 of the Public Health Code
- Article 1245-3 of the Civil Code
- Article 1245-8 of the Civil Code
- Article 1245-9 of the Civil Code
- Article 1245-10 of the Civil Code
- Article L. 5121-31 of the Public Health Code
- Article L. 5121-32 of the Public Health Code
- Article L. 5125-9 of the Public Health Code
- Article L. 5125-11 of the Public Health Code
- Article L. 5125-12 of the Public Health Code
- Article L. 5125-18 of the Public Health Code
- Article R. 5125-18 of the Public Health Code
- Article R. 5125-24-2 of the Public Health Code
- Article L. 5127-1 of the Public Health Code
- Article L. 5472-1 of the Public Health Code
- Article L. 5472-2 of the Public Health Code
- Article R. 5125-18-1 of the Public Health Code
- Article R. 5125-19 of the Public Health Code
- Article R. 5125-71 of the Public Health Code
Related pages and publications
The publications complement this page according to their subject. This page presents only the assistance offered to professionals in the pharmaceutical sector.
A pharmacy project or a procedure to examine?
Present your project or send the notification you received with the relevant documents. The firm examines the situation, the documents available and the steps to be considered. It can be reached 24/7, and the preliminary case review can be requested using the form on this page.



